# Phase Ia Clinical Study of HDM1005 Injection

> **NCT06640647** · PHASE1 · COMPLETED · sponsor: **Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.** · enrollment: 65 (actual)

## Conditions studied

- Obesity and Overweight

## Interventions

- **DRUG:** HDM1005 injection or placebo

## Key facts

- **NCT ID:** NCT06640647
- **Lead sponsor:** Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-19
- **Primary completion:** 2024-08-06
- **Final completion:** 2024-09-26
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06640647

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06640647, "Phase Ia Clinical Study of HDM1005 Injection". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06640647. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*